US$ 27.43
fda glp-1 compounding enforcement november 2025 π¨ Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale of medications like semaglutide and tirzepatide, signaling a major shift in how these GLP-1 Drugs: Brand Companies Push
Description
Huge congratulations to the authors!

Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity

Novo Nordisk has launched the Medicare GLP-1 Bridge, making Wegovy available to eligible Medicare beneficiaries for $50 a month through the end of 2027, giving millions of older adults with obesity a structured pathway to the FDA-approved weight management drug.

Open 5 Days A Week.

The comprehensive adverse effe...
